Takeda licenses microbiome IBD candidate from Finch Therapeutics
Finch Therapeutics Inc. granted Takeda Pharmaceutical Co. Ltd. exclusive global rights to develop and sell its microbiome candidate FIN524, which is in preclinical studies for inflammatory bowel disease.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com